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tetrahydrofuranAbstract A screening of various cerium salts for promoting the Paal–Knorr pyrrole synthesis
revealed the superiority of cerium (IV) ammonium nitrate (CAN) as a catalyst. Excellent yields
of substituted pyrroles were obtained in CAN-catalyzed Paal–Knorr reactions of 1,4-diketones with
various amines. The protocol is noteworthy for the mild reaction condition, short reaction times,
scalability and easy isolation of products and high yields of the products.
ª 2013 Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
The pyrrole nucleus is, perhaps, the most important heterocycle
abundantly found in bioactive natural molecules such as por-
phyrins and alkaloids (Katrizky, 2004; Sundberg, 1996). Pyr-role ring is also present in various drugs including many anti-
inﬂammatants, immunosuppressants, COX-2 inhibitors, anal-
gesic, antitubercular agents (Zhou and Giannakakou, 2005;
Li et al., 1999; Doherty, 2004; Gribble, 1996; Biava et al.,
2010) as well as the highly successful cholesterol-lowering drug
atorvastatin (Lipitor, Fig 1), (Sawant and Maier, 2010). Addi-
tionally, pyrrole with 1,2,5-trisubstitution pattern exhibits
remarkable biological properties as illustrated by the anti-
inﬂammatory agents amtolmetin and tolmetin (Fig. 1), (Shue
et al., 2004; Bertaccini and Coruzzi, 1998). As a result of their
pharmaceutical signiﬁcance, a number of methods have been
developed for the preparation of substituted pyrroles. These in-
clude the Hantzsch reaction (Hantsch, 1890), conjugate addi-
tion reaction (Dieter and Yu, 2000), reductive coupling
(Furstner et al., 1995), aza-Wittig reaction (Katrizky et al.,
1994), and other multistep operations (Periasamy et al., 1999).
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Figure 1 Some pyrrole-containing drugs.
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diketone is condensed with an amine, continues to be the most
attractive method for the synthesis of pyrroles (Wang et al.,
2004; Banik et al., 2005; Danks, 1999; Chen et al., 2006; Agha-
poor et al., 2012). Despite its popularity, the Paal–Knorr reac-
tion suffers from limitations such as drastic reaction
conditions, high cost, poor yields, tedious workup and longer
reaction time. Therefore, the development of milder and non-
hazardous methods for pyrrole synthesis continues to be a very
important area of investigation.
2. Results and discussion
In continuation of our ongoing investigations on the develop-
ment of useful synthetic protocols suitable for applications in
the ﬁeld of combinatorial chemistry and chemistry-driven drug
discovery (Kamal et al., 2007a,b, 2009, 2010) we undertook a
study directed at developing cerium based catalysts for pro-
moting the Paal–Knorr reaction under mild conditions. The
results obtained in this study are presented in the following
sections.
Cerium salts are inexpensive, soluble in many organic sol-
vents, stable under aerobic condition and are less toxic. The
most important cerium based reagent in organic synthesis is
indubitably cerium (IV) ammonium nitrate (CAN), the
usefulness of which was amply demonstrated by a wide array
of synthetic transformations developed by Nair and Deepthi
(2007).Table 1 Screening of the different cerium salts as catalysts for the
Entry Catalyst (oxidation state) Catalyst l
1 CeCl3 (III) 20
2 CeCl3 (III) 10
3 Ce(SO4)2 (IV) 20
4 Ce(SO4)2 (IV) 10
5 CAN (IV) 20
6 CAN (IV) 10
7 CAN (IV) 5
8 CAN (IV) 2.5
9 None –
a Isolated yields after chromatography.The cerium salts selected for the study were cerium (III)
chloride, cerium (IV) sulfate and CAN. They were screened
as catalysts in the reaction between aniline 1 and hexane-2,5-
dione 2 in methanol at room temperature and CAN emerged
as a superior catalyst in terms of yields, catalyst loading and
reaction time (Table 1).
In an attempt to ﬁnd the optimum reaction conditions and
to improve the overall efﬁciency of this CAN catalyzed Paal
Knorr reaction, we examined the effect of the concentration
of catalyst and the solvent used. It was observed that at a con-
centration of 5 mol percent, CAN provides the best results
with 96% of pyrrole formation in 15 min. However, the de-
crease in concentration of CAN from 5% to 2.5% resulted
in lower yields (Entry 7–8, Table 1). Additionally, the reaction
was carried out in different organic solvents and a direct cor-
relation between solubility of CAN (and polarity) and yield
was observed (Tou-
lene < CH2Cl2 < CH3CN< EtOH<MeOH). The yields of
product in different solvents are in a fashion as Toluene (yield:
35%) < CH2Cl2 (yield: 45%) < CH3CN (yield:
75%) < EtOH (yield: 90%) <MeOH (yield: 96%)). More-
over, the reaction was also performed in the most polar solvent
water, and the experimental yield after puriﬁcation was 25%.
The optimized reaction conditions were then applied for the
synthesis of a sortiment of 2,5-dimethyl pyrroles by the reac-
tion of 2 with a series of aliphatic, heterocyclic and benzylic
amines (Table 2). The addition of catalytic amount of CAN
(5 mol%) typically resulted in the completion of the reaction
within 10–20 min at ambient temperature. It is noteworthy
that this protocol for the synthesis of pyrroles from polycyclic
aromatic aniline (Table 2, Entry g) and heterocyclic amines
(Table 2, Entry j, l, and r). Other notable pyrrole derivatives
that were accessible by this method include N-phthalimido
pyrrole 3i and the bis-pyrrole 3k. The use of nearly equimolar
amounts of substrates in this protocol is advantageous when
compared to the conventional methods that use excess of
amine in order to promote the condensation (Curuni et al.,
2003). Moreover, as no strong acid is used, the present method
does not require neutralization after completion of the reac-
tion. Finally, the method was scaled up to generate multigram
quantities of pyrroles without any signiﬁcant loss in yields.
Diaryl pyrroles constitute an important and privileged
structural motif in the context of medicinal chemistry
applications (Biava et al., 2010). In order to access these valu-
able pyrrole derivatives, substituted aryl diketones were em-
ployed in the CAN-catalyzed condensations (Table 3).
Pleasingly, the reactions afforded a number of diaryl pyrrolesreaction of aniline (1) with hexane-2-5-dione (2).
oading (mol%) Time (h) Yields (%)a
24 45
24 20
3 35
4 45
0.75 65
0.25 90
0.25 96
1 85
24 –
Table 2 Synthesis of 1,3,5-substituted pyrroles from primary amines (1a–r) and diketone 2a using catalytic amount of CAN.
O
O
N
R1a-r
CAN, 5 mol%
MeOH, RT
3a-r
2a
R = alkyl, aryl, heteryl
RNH2 +
Entry Substrate (1a-r) Product (3a-r) Time (min) Yield (%)a
a
NH2
N
15 95
b
NH2MeO
NMeO
15 88
c NH2
OMe
MeO
N
OMe
MeO
15 84
d
NH2HO
NHO
15 93
e
NH2F
F
NF
F
16 92
f
NH2HOOC
HOOC N
17 75
g NH2
N
16 94
h Ph–H2C–NH2
H2CPh N
15 92
(continued on next page)
544 A. Kamal et al.
Table 2 (continued)
i
N
O
O
NH2 N
O
O
N
15 93
j
N
NH2
N
N
18 75
kb NH2(CH2)NH2
H2C CH2N N
18 88
l
S
NH2N
S
NN
17 85
m F
N NH2N
F
N NN
15 88
n F
N NH2N
N
F
N NN
N
16 89
o F
N NH2NMeO
F
N NNO
15 88
p F
N NH2N
O
Ph
F
N NN
O
Ph
18 84
q F
N NH2N
O
F
N NN
O
15 85
r
N
H
N
H2N
N
H
N
N
18 83
a Isolated yield after column chromatography.
b Two equivalents of diketone 2a used.
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Table 3 CAN-catalyzed synthesis of diaryl pyrrole from anilines and aryl diketones.
N
R1
O
O+
NH2
R1
CAN (5 mol %)
MeOH, RT
1
R2 = H, F, Cl, OMe
R3 = H, CO2Et
3s-w
R2R2
2
R3 R3
R1 = H, F, Cl, NO2
Entry Amine Diketone Product Time (min) Yield (%)a
s
F
NH2 O
O
Cl
N
F
Cl 15 92
t
F
NH2 O
O
F
N
F
F
15 93
u
Cl
NH2 O
O
Cl
N
Cl
Cl
16 95
v
F
NH2 O
O
F
F
N
F
F
F
18 90
w NH2 O
O
MeO
COOEt
N
MeO
COOEt 15 88
a Isolated yield after column chromatography.
CAN, 5 mol%
MeOH, RT, 15 min
+
OMeO OMe
NH2 N
x
2g1a
Scheme 2 B.
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Scheme 1 A.
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(Table 3).
Nair has reported that CAN effectively catalyzes the hydro-
lysis of acetals21 and this property was exploited in a one-pot
synthesis of N-substituted pyrrole (1a) from 2,5-dimethoxytet-
rahydrofuran (2g) and primary amines. It is presumable that
CAN initially deprotects the acetal functionality and subse-
quently promotes the Paal–Knorr reaction (Scheme 2). (See
Scheme 1).3. Conclusion
In summary, the present CAN-catalyzed protocol provides a
mild, efﬁcient and practical variant of the Paal–Knorr pyrrole
synthesis. Excellent yields of variously substituted pyrroles are
obtained under ambient reaction conditions. Continued inves-
tigations to generate libraries of substituted pyrrole derivatives
for applications in the ﬁeld of chemistry-driven drug discovery
are currently underway and the results will be reported in due
course.4. Experimental
4.1. General remarks
Melting points were determined with an electrothermal melt-
ing point apparatus and are uncorrected. Infrared (IR) spectra
were recorded on a Perkin–Elmer model 683 or 1310 spectrom-
eters with sodium chloride optics. 1H NMR spectra were re-
corded on an Avance 300 MHz spectrometer (Bruker,
Fallanden, Switzerland) and 13C NMR spectra were recorded
on a UNITY 400 MHz (Varian, Switzerland). Chemical shifts
(d) are reported in ppm, downﬁeld from internal TMS stan-
dard. Mass spectra were recorded using a quadruple ion trap
mass spectrometer (Thermo Finnign, San Jose, CA, USA)
equipped with an electro spray source.
4.2. A representative experimental procedure for pyrrole
synthesis
To a solution of aniline (10 mmol) and hexane-2, 5-dione
(10 mmol) in methanol (5 mL) at room temperature, cerium
ammonium nitrate (0.5 mmol) was added. The mixture was al-
lowed to stir at room temperature for 15 min and after the
completion of reaction as indicated by TLC; the solvent was
evaporated under reduced pressure. The residue was redis-
solved in ethyl acetate (30 mL) and washed with water
(15 mL). The organic layer was dried using brine and traces
of water were removed using anhydrous sodium sulfate and
concentrated in vacuo. The resulting residue was puriﬁed by
silica gel column chromatography using EtOAc: petroleum
ether (1:10) to afford the pure product.
4.2.1. 2,5-Dimethyl-1-phenyl-1H-pyrrole 3a
Solid, mp. 45–48 C. IR (KBr): (tmax): 3098, 3054, 2972, 2922,
2738, 1960, 1596, 1495 cm1; 1H NMR (CDCl3, 300 MHz): d
2.03 (s, 6H), 5.9 (s, 2H), 7.21 (m, 2H), 7.36–7.43 (m, 3H); 13C
NMR (100 MHz, CDCl3): 12.85, 106.33, 127.81, 128.41,
128.84, 128.23, 139.18; LC–MS: m/z: 194 (M+ Na)+.4.2.2. 1-(4-Methoxyphenyl)-2,5-dimethyl-1H-pyrrole 3b
Solid, mp. 55–57 C. 1H NMR ((CDCl3, 300 MHz): d 2.0 (s,
6H), 3.72(s, 3H), 7.65 (d, J= 7.2 Hz, 2H), 7.87
(d, J= 7.2 Hz, 2H) 13C NMR (100 MHz, CDCl3): 12.5,
55.3, 105.4, 126.1, 127.7, 130.2, 156.9; LC–MS: m/z: 201
(M+ 1)+.
4.2.3. 1-(2,4-Dimethoxyphenyl)-2,5-dimethyl-1H-pyrrole 3c
Solid, mp. 50–52 C. 1H NMR (CDCl3, 300 MHz): d 1.97(s,
6H), 3.75(s, 3H), 3.87 (s, 3H), 5.89 (s, 2H), 6.55 (d, 1H,
J= 8.90 Hz), 6.95 (s, 1H), 7.08 (d, 1H, J= 8.90 Hz); LC–
MS: m/z: 232 (M+ 1)+.
4.2.4. 4-(2,5-Dimethyl-1H-pyrrol-1-yl)phenol 3d
Solid, mp. 39–42 C. 1H NMR (CDCl3, 300 MHz): d 2.01 (s,
6H), 5.87 (s, 2H), 6.88 (d, 2H, J= 6.14 Hz), 7.05 (d, 2H,
J= 6.14 Hz); LC–MS: m/z: 188 (M+ 1)+.
4.2.5. 1-(3,4-Diﬂuorophenyl)-2,5-dimethyl-1H-pyrrole 3e
Solid, mp. 55–57 C. 1H NMR (CDCl3, 300 MHz): d 2.01 (s,
6H), 5.82 (s, 2H), 7.2–7.3 (m, 3H). 13C NMR (300 MHz)
12.5, 106, 108.2, 117.3(d), 125.8, 138.7, 146, 145.6; LC–MS:
m/z: 208 (M+ 1)+.
4.2.6. 4-(2,5-Dimethyl-1H-pyrrol-1-yl)benzoic acid 3f
Solid, mp. 63–65 C. IR (KBr): (tmax): 3439, 3058, 3054,
2921, 2855, 1960, 1650, 1516, 1442, 1263 cm1; 1H NMR
(CDCl3, 300 MHz): d 2.05 (s, 6H), 5.84 (s, 2H), 7.31 (d,
J= 8.309 Hz, 2H), 8.24 (d, J= 8.309 Hz, 2H); 13C NMR
(400 MHz, CDCl3): 13.03, 106.24, 127.77, 127.88, 128.15,
130.71, 143.51, 171.11; LC–MS: m/z: 216 (M+ 1)+.
4.2.7. 2,5-Dimethyl-1-(naphthalen-1-yl)-1H-pyrrole 3g
Solid, mp. 60–62 C. 1H NMR (CDCl3, 300 MHz): d 2.08(s,
6H), 5.91(s, 2H), 7.06(t, 1H, J= 7.93 Hz), 7.77 (t, 1H,
J= 7.93 Hz), 7.82 (d, 1H, J= 8.12 Hz), 8.01 (d, 1H), 8.19,
(d, 1H), 8.78 (d, 1H); LC–MS: m/z: 222 (M+ 1)+.
4.2.8. 1-Benzyl-2, 5-dimethyl-1H-pyrrole 3h
Solid, mp. 55–57 C, 1H NMR (CDCl3, 300 MHz): d 2.16(s,
6H), 5.02 (s, 2H), 5.80(s, 2H), 6.88 (d, 2H, J= 6.7 Hz),
7.27–7.32 (m, 3H). 13C NMR (400 MHz, CDCl3): 11.64,
46.25, 105.36, 125.17, 126. 52, 127.56, 128.24, 138.07; LC–
MS: m/z: 186 (M+ 1)+.
4.2.9. 2-(2,5-Dimethyl-1H-pyrrol-1-yl)isoindoline-1,3-dione 3i
Solid, mp. 103–105 C. IR (KBr): (tmax): 3438, 3057, 2923,
1790, 1745, 1533, 1452, 1354, 1258, 1110 cm1; 1H NMR
(CDCl3, 300 MHz): d 2.03 (s, 6H), 5.86 (s, 2H), 7.85–7.86 (d,
J= 3.2 Hz, 2H), 7.97 (d, J= 3.2 Hz, 2H); 13C NMR
(100 MHz, CDCl3): d 10.49, 104.96, 123.84, 127.57, 129.10,
134.62, 164.24; LC–MS: m/z: 241 (M+Na)+.
4.2.10. 4-((2, 5-Dimethyl-1H-pyrrol-1-yl)methyl)pyridine 3j
Solid, mp. 98–100 C. 1H NMR (CDCl3, 300 MHz): d 2.11 (s,
6H), 4.99(s, 2H), 5.87 (s, 2H), 6.78 (d, 2H, J= 5.21 Hz), 8.51
(d, 2H, J= 5.21 Hz). 13C NMR 13.15, 46.16, 107.13, 121.14,
128.12, 148.59, 150.50; LC–MS: m/z: 187 (M+ 1)+.
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Solid, mp. 60–62 C. 1H NMR (CDCl3, 300 MHz): d 1.96 (s,
12H), 3.9 (s, 4H), 5.65 (s, 4H). 13C NMR: 12, 4, 43.60, 106,
129; LC–MS: m/z: 217 (M+ 1)+.
4.2.12. 5-(2,5-Dimethyl-1H-pyrrol-1-yl)benzo[d]thiazole 3l
Solid, mp. 100–102 C. 1H NMR (CDCl3, 300 MHz): d 205 (s,
6H), 5.94 (s, 2H), 7.36 (d, 1H, J= 8.30 Hz), 7.81 (d, 1H,
J= 1.51 Hz), 8.19 (d, 1H, J= 8.30 Hz), 9.07 (s, 1H); LC–
MS: m/z: 229 (M+ 1)+.
4.2.13. 1-(4-(2,5-Dimethyl-1H-pyrrol-1-yl)-2-ﬂuorophenyl)-4-
phenylpiperazine 3m
Solid, mp. 98–100 C. 1H NMR (CDCl3, 300 MHz): d 2.035 (s,
6H), 3.32 (t, 4H), 3.38 (t, 4H), 5.87 (s, 2H), 6.89–7.04 (m, 5H),
7.25 (s, 1H), 7.30 (2H); LC–MS: m/z: 351 (M+ 1) +.
4.2.14. 1-(4-(2,5-Dimethyl-1H-pyrrol-1-yl)-2-ﬂuorophenyl)-4-
(pyridin-2-yl)piperazine 3n
Solid, mp. 111–113 C. 1H NMR (CDCl3, 300 MHz): d 2,03 (s,
6H), 3.27(t, 4H, J= 5.28, 4.53 Hz), 3.74 (t, 4H, J= 5.28,
3.74), 5.88(s, 2H), 6.74–6.65 (m, 2H), 6.9–7.05 (m, 3H), 7.52
(dt, 1H), 8.24 (dd, 1H). 13C NMR (100 MHz, CDCl3): 12.91,
44.40, 50.53, 105.60, 107.20, 113.69, 116.12, 116.48, 118.16,
118.72, 124.28, 124.32, 128.90,132.26, 137.38,145.98, 147.43;
LC–MS: m/z: 351 (M+ 1)+.
4.2.15. 1-(4-(2,5-Dimethyl-1H-pyrrol-1-yl)-2-ﬂuorophenyl)-4-
(4-methoxyphenyl)piperazine 3o
Solid, mp. 114-116 C. 1H NMR (CDCl3, 300 MHz): d 2.05 (s,
6H), 3.28 (t, 4H, J= 5.52 Hz), 3.32 (t, 4H), 3.89 (s, 3H), 5.88
(s, 2H), 6.8 (d, 2H, J= 8.3 Hz), 6.90–7.06 (m, 5H); LC–MS:
m/z: 380 (M+ 1)+.
4.2.16. (4-(4-(2,5-Dimethyl-1H-pyrrol-1-yl)-2-
ﬂuorophenyl)piperazin-1-yl)(phenyl) methanone 3p
Solid, mp. 107–109 C. 1H NMR (CDCl3, 300 MHz): d 2.02 (s,
6H), 5.87(s, 2H), 6.91–7.01 (m, 3H), 7.4 (m, 5H); LC–MS: m/z:
377 (M+ 1)+.
4.2.17. 1-(4-(2,5-Dimethyl-1H-pyrrol-1-yl)-2-ﬂuorophenyl)-4-
(2-methoxyphenyl)piperazine 3q
Solid, mp. 115–117 C. 1H NMR (CDCl3, 300 MHz): d 2.04 (s,
6H), 3.29 (t, 4H, J= 5.24 Hz), 3.35 (t, 4H, J= 4.198), 3.91 (s,
3H), 5.88 (s, 2H), 6.90 (d, 1H, J= 8.35 Hz), 6.95 (d, 1H,
J= 8.35 Hz), 6.98 (s, 1H), 7.02 (dd, 1H, J= 6.29 Hz), 7.04,
(dd, 1H, J= 8.35 Hz), 7.07 (d, 1H, J= 3.14 Hz); LC–MS:
m/z: 380 (M+ 1)+.
4.2.18. 5-(2,5-Dimethyl-1H-pyrrol-1-yl)-1H-indazole 3r
Solid, mp. 120–122 C. 1H NMR (CDCl3, 300 MHz): d 2.02,
(s, 6H), 5.97(s, 2H), 7.21 (d, 1H, J= 1.51 Hz), 7.24(s, 1H),
7.55(s, 1H), 7.58(s, 1H), 7.61(d, 1H, J= 1.51 Hz), 8.13(s,
1H); LC–MS: m/z: 212 (M+ 1) +.
4.2.19. 1-(4-Fluorophenyl)-2-methyl-5-(2-chlorophenyl)1H-
pyrrole 3s
Solid, mp. 125–127 C (yield 60%); 1H NMR (CDCl3,
300 MHz) 2.09 (s, 3H), 6.10–6.11(m, 1H), 6.28 (m, 1H),6.96(2H, m), 7.03–7.10 (m, 4H), 7.25(m, 2H); LC–MS: m/z:
286 (M+ 1) +.
4.2.20. 1,2-Bis(4-Fluorophenyl)-5-methyl-1H-pyrrole 3t
Solid, mp. 113–116 C. IR (KBr): (tmax): 3070, 2960, 2928,
2837, 2737, 2055, 1866, 1744, 1614, 1589, 1511, 1227 cm1;
1H NMR (CDCl3, 300 MHz): d 2.10 (s, 3H), 5.98 (d,
J= 3.39 Hz, 1H), 6.19 (d, J= 3.39 Hz, 1H), 6.81 (t, 2H),
6.97–6.72 (m, 2H), 7.12 (m, 4H); 13C NMR (100 MHz,
CDCl3): 12.69, 76.13, 76.56, 76.99, 107.10, 108.12, 114.33,
114.62, 115.33, 115.63, d 128.99, d 129.56, 131.08, 132.78, d
134.72, 159.10, d 159.49, d 162.58; LC–MS: m/z: 270
(M+ 1)+.
4.2.21. 1,2-Bis(4-chlorophenyl)-5-methyl-1H-pyrrole 3u
Solid, mp. 115–117 C. 1H NMR (CDCl3, 300 MHz) d 2.10 (s,
3H), 6.29 (d, 1H, J= 2.32 Hz), 6.34 (d, 1H, J= 2.32 Hz), 6.94
(m, 2H), 6.97 (m, 2H), 7.03 (m, 2H), d 7.10 (m, 2H); LC–MS:
m/z: 303 (M+ 1)+.
4.2.22. 2-(2,4-Diﬂuorophenyl)1-(4-ﬂuorophenyl)-5-
methylpyrrole 3v
Solid, mp. 119–121 C. 1H NMR (CDCl3, 300 MHz): d 2.15 (s,
3H), 6.11 (d, 1H, J= 3.7 Hz), 6.30 (dd, 1H, J= 3.7 Hz), 6.65–
6.76 (m, 2H, J= 9.0 Hz), 7.04–7.00 (m, 2H), 7.12–7.05 (m,
3H, J= 5.2 Hz); LC–MS: m/z: 288 (M+ 1)+.
4.2.23. Ethyl 5-(4-Methoxyphenyl)-2-methyl-1-phenyl-1H-
pyrrole-3-carboxylate 3w
Solid, mp. 111–115 C C. IR (KBr): (tmax): 3438, 3057, 2923,
1790, 1745, 1533, 1452, 1354, 1258, 1110 cm1; 1H NMR
(CDCl3, 300 MHz): d 1.15 (t, J= 6.81 Hz, 3H), 2.42 (s, 3H),
3.77 (s, 3H), 4.14 (q, J= 6.81 Hz, 2H), 6.60 (s, 1H) 6.81 (d,
J= 8.51 Hz, 2H) 7.24–7.29 (m, 5H) 7.41 (d, J= 8.51 Hz,
2H) 13C NMR (100 MHz, CDCl3): d 10.49, 104.96, 123.84,
127.57, 129.10, 134.62, 164.24; LC–MS: m/z: 336 (M+ 1)+.
4.2.24. 1-Phenyl-1H-pyrrole 3x
Solid, mp. 40–43 C. 1H NMR (CDCl3, 300 MHz): d 6.26 (s,
2H), 7.00 (s, 2H), 7.17–7.32 (m, 5H); LC–MS: m/z: 144
(M+ 1)+.Acknowledgments
The authors (SF, MB and SB) are thankful to Council of Sci-
entiﬁc and Industrial Research (CSIR) for ﬁnancial support
under the XIIth Five Year plan project ‘‘Affordable Cancer
Therapeutics’’ and for the award of fellowship to one of the
authors (SB) and University Grant Commission (UGC) for
the authors (SF and MB).
References
Aghapoor, Kioumars, Ebadi-Nia, Leila, Mohsenzadeh, Farshid,
Morad, Mina Mohebi, Balavar, Yadollah, Darabi, Hossein Reza,
2012. J. Organomet. Chem., 708.
Banik, B.K., Banik, I., Renteriaa, M., Dasgupta, S.K., 2005. Tetra-
hedron Lett. 46, 2643.
Bertaccini, G., Coruzzi, G., 1998. Gastroenterology 114, 72.
Convenient synthesis of substituted pyrroles via a cerium (IV) ammonium nitrate (CAN)-catalyzed 549Biava, M., Porretta, G.C., Poce, G., Battilocchio, C., Manetti, F.,
Botta, M., Forli, S., Sautebin, O. L., Rossi, A., Pergola, C.,
Ghelardini, C., Galeotti, N., Makovec, F., Giordani, A., Anzellotti,
P., Patrignani, P., Anzini, M., 2010. J. Med. Chem. 53, 723 and
references cited therein.
Chen, J., Wu, H., Zheng, Z., Jin, C., Zhang, X., Su, W., 2006.
Tetrahedron Lett. 47, 5383.
Curuni, M., Montanari, F., Rosati, O., Lioy, E., Margarita, R., 2003.
Tetrahedron Lett. 44, 3923.
Danks, T.N., 1999. Tetrahedron Lett. 40, 3957.
Dieter, R.K., Yu, H., 2000. Org. lett. 2, 283.
Doherty, A.M., 2004. Annual Reports in Medicinal Chemistry.
Elsevier, Amstrdam, vol. 39.
Furstner, A., Weintritt, H., Hupperts, A., 1995. J. Org. Chem. 60,
6637.
Gribble, G.W., 1996. Comprehensive Heterocyclic Chemistry II. In:
Katritzky, A.R., Rees, C.W., Scriven, E.F.V. (Eds.), Pergamon
Press, Oxford, vol. 2, p. 207.
Hantsch, A., 1890. Ber. Dtsch. Chem. Ges. 23, 1474.
Kamal, A., Devaiah, V., Reddy, K.L., Rajendar, Shetti,
R.V.C.R.N.C., Shankaraiah, N., 2007a. J. Comb. Chem, 267.
Kamal, A., Reddy, K.L., Devaiah, V., Shankaraiah, N., Reddy,
G.S.K., Raghavan, S., 2007b. J. Comb. Chem. 9, 29.Kamal, A., Nagula, M., Nagula, S.C., Reddy, R., Prabhakar, S.,
Reddy, C.S., Marcos, E.N., Leonardo, S.S., 2009. Chemistry
(Weinheim an der Bergstrasse, Germany) 15, 7215.
Kamal, A., Ashwini, B.K., Suresh, P., Shankaraiah, N., Shiva Kumar,
M., 2010. Bioorg. Med. Chem. Lett. 21, 350.
Katrizky, A.R., 2004. Chem. Rev. 125, 1042.
Katrizky, A., Jiang, J., Steel, P.J., 1994. J. Org. Chem. 59, 4551.
Li, Q., Sham, H.L., Rosenberg, S.H., 1999. Ann. Rep. Med. Chem. 34,
139.
Nair, V., Deepthi, A., 2007. Chem. Rev. 107, 1862, and references
therein.
Periasamy, M., Srinivas, G., Bharati, P., 1999. J. Org. Chem. 64, 4204.
Sawant, P., Maier, Martin E., 2010. Tetrahedron 66, 9738.
Sheu, Ming-Thau, Wu, Jender, Chen, Chih-Jui, Chao, Su-Hui, Wua,
An-Bang, 2004. Tetrahedron Lett. 45, 8107.
Sundberg, R.J., 1996. In Comprehensive Heterocyclic Chemistry. In:
Katritzky, A.R., Rees, C.W., Scriven, E.F.V. (Eds.). Pergamon,
Oxford, vol. 2, p. 119.
Wang, B., Gu, Y., Luo, C., Yang, T., Yang, L., Suo, J., 2004.
Tetrahedron Lett. 45, 3417.
Zhou, J., Giannakakou, P., 2005. Curr. Med. Chem. Anticancer
Agents 5, 65.
